Daniel Ahn

Sep 23, 2024 | cancernetwork.com | Daniel Ahn |Rahul Gosain |Rohit Gosain

Advanced HCC: Key Takeaways Key opinion leaders summarize essential takeaways and highlight unmet needs in the hepatocellular carcinoma treatment landscape. What are some key takeaways from this analysis? What are some clinical pearls you wish to offer your community colleagues who are considering treating their patients with atezo + bev? (EGD consideration, etc)What are some unmet needs in the treatment of advanced HCC?

Sep 23, 2024 | cancernetwork.com | Daniel Ahn |Rahul Gosain |Rohit Gosain

The panel reviews the CheckMate 9DW study design and evaluates its safety data.

Sep 16, 2024 | cancernetwork.com | Daniel Ahn |Rahul Gosain |Rohit Gosain

Medical experts analyze the exploratory efficacy and safety results for patients with portal vein invasion (Vp4), addressing the challenges in treating this subgroup.

Sep 16, 2024 | cancernetwork.com | Daniel Ahn |Rahul Gosain |Rohit Gosain

September 16, 2024By Key opinion leaders examine IMbrave 150 data stratified by baseline varices and compare outcomes between patients with Child-Pugh A and B. Video content above is prompted by the following: Please share your thoughts on the data based on baseline varices from IMbrave 150. Concerning safety data, is this in line with you what you see in practice for the vp4 and baseline varices? How do you currently manage AEs seen in practice?

Sep 9, 2024 | cancernetwork.com | Daniel Ahn |Rahul Gosain |Rohit Gosain

Key opinion leaders share their impressions of the IMBrave150 trial data and discuss their real-world clinical experiences using atezolizumab plus bevacizumab in practice.